AstraZeneca's new antibiotic comes through in Phase III

AstraZeneca's ($AZN) antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot at regulatory approval. The treatment is a blend of the antibacterial agents ceftazidime and avibactam, dubbed CAZ-AVI, designed to treat a broad range of Gram-negative bacterial infections that are rapidly becoming resistant to standard therapy. In two Phase III trials, CAZ-AVI significantly improved cure rates of complicated intra-abdominal infections compared with the tried-and-true injectable meropenem, providing the basis for regulatory filings next year, AstraZeneca said. The treatment, also being studied in urinary tract infections and pneumonia, is part of a collaboration with Actavis' ($ACT) Forest Laboratories. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.